Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881116 | 0.89 | HTR1A (0.42) | HTR6HTR1AADRA2ASIGMAR1MEN1 | |
| SCHEMBL3877938 | 0.84 | KDM4E (0.50) | HTR6HTR1AADRA2AMEN1KMT2A | |
| SCHEMBL3885118 | 0.77 | KDM4E (0.50) | HTR6HTR1AADRA2AMEN1KMT2A | |
| SCHEMBL12316118 | 0.75 | HTR6 (0.49) | HTR6HTR1AHTR2CHTR7 | |
| SCHEMBL13899949 | 0.75 | HTR6 (0.36) | HTR6HTR1ATRPV1HTR2CHTR7 | |
| SCHEMBL3948426 | 0.75 | HTR6 (0.51) | HTR6HTR2C | |
| SCHEMBL3874512 | 0.72 | KIF11 (0.44) | HTR6HTR1AADRA2ASIGMAR1 | |
| SCHEMBL4031402 | 0.70 | BRD4 (0.53) | HTR6HTR1AKMT2AHTR2CHTR7 | |
| SCHEMBL3874258 | 0.69 | BAZ2B (0.46) | HTR1ASIGMAR1MEN1KMT2AATM | |
| SCHEMBL12316089 | 0.69 | HTR6 (0.53) | HTR6HTR1AMEN1KMT2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919475-B1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | ESTEVE LABOR DR (ES) | 2009-03-11 | — | — | EP | claimed |
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | disclosed |
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | disclosed |
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2008-11-13 | — | — | US | disclosed |
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2008-11-13 | — | — | US | disclosed |
| WO-2007028460-A1 | TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | HTR6, HTR5A, HTR1B | HTR6 1/4885BCHE 568/4885HTR1A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.